News Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Market Closed - Nasdaq Other stock markets 21:30:00 26/04/2024 BST			5-day change	1st Jan Change
0.3427 ^USD	+0.76%		+6.73%	-43.82%

03-21	Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-05	Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Dermata Therapeutics : Provides Corporate Update and Reports Full Year 2023 Financial Results - Form 8-K	03-21	PU
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Dermata to Present at the Emerging Growth Conference on February 7, 2024	02-02	AQ
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	01-05	MT
Top Premarket Gainers	01-05	MT
North American Morning Briefing : Bond Yields Rise Again as Jobs Data Loom	01-05	DJ
Dermata Therapeutics, Inc. Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne	12-20	CI
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols	11-17	AQ
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	11-16	MT
Dermata Therapeutics to Begin Enrolling Patients in Acne Drug Study; To Raise $2.3 Million	11-16	MT
Dermata Therapeutics, Inc. to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 Based on Agreement with FDA on the Phase 3 Protocols	11-16	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Dermata Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Dermata Therapeutics, Inc. Announces Positive Feedback from FDA on the DMT310 Phase 3 Clinical Development Program in Moderate-To-Severe Acne	27/06/23	CI
Dermata Therapeutics, Inc. Announces Positive Results from its DMT310 Phase 2b Study of Its Once-Weekly Topical Treatment in Patients with Moderate-To-Severe Acne Vivis	08/06/23	CI
Dermata Therapeutics Completes $1.8 Million Share Offering	26/05/23	MT
DERMATA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24/05/23	AQ
Certain Warrants of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	15/05/23	CI
Certain Common Stock of Dermata Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-MAY-2023.	15/05/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Summary

Filters